ArticleMolecular diversity2026
Design, synthesis and antitumor activity of thiadiazole derivatives as novel ALK kinase inhibitors.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
In recent years, the number of patients with ALK-positive NSCLC has increased, along with the emergence of various resistance mutations. To address the resistance issues caused by ALK mutations, this study used Crizotinib as the lead compound and modified its side chain to design and synthesize a series of compounds containing thiadiazole structures. The compounds were evaluated through tyrosine kinase inhibition assays and cellular experiments. The results show that compound B11 exhibits strong cytotoxic activity against the NSCLC NCI-H2228 cell line. Moreover, B11 demonstrates a dose-dependent effect, inhibiting NCI-H2228 cell viability, inducing G0/G1-phase cell cycle arrest, and promoting cell death. More importantly, compound B11 overcomes the resistance caused by the ALK
Indexed as
Identifiers
40544413What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.